Danaher Corporation $DHR Shares Bought by Stableford Capital II LLC

Stableford Capital II LLC lifted its holdings in Danaher Corporation (NYSE:DHR) by 292.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,766 shares of the conglomerate’s stock after buying an additional 13,984 shares during the quarter. Danaher comprises 1.4% of Stableford Capital II LLC’s portfolio, making the stock its 17th biggest holding. Stableford Capital II LLC’s holdings in Danaher were worth $4,158,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. EP Wealth Advisors LLC bought a new position in Danaher in the 2nd quarter valued at $3,807,000. Puzo Michael J bought a new stake in shares of Danaher during the second quarter worth $8,624,000. Madison Asset Management LLC acquired a new position in shares of Danaher during the second quarter valued at $85,451,000. First Nebraska Trust Co acquired a new position in shares of Danaher during the second quarter valued at $14,106,000. Finally, Colton Groome Financial Advisors LLC bought a new position in shares of Danaher in the 3rd quarter valued at about $592,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $217.33 on Friday. The firm has a market cap of $152.78 billion, a price-to-earnings ratio of 38.60, a P/E/G ratio of 2.72 and a beta of 0.76. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock’s fifty day moving average price is $210.88 and its two-hundred day moving average price is $194.44.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the firm posted $0.77 EPS. Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. On average, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is currently 28.42%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several recent research reports. Piper Sandler began coverage on Danaher in a research report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price target on the stock. Barclays boosted their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday. Wells Fargo & Company reduced their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. Finally, UBS Group began coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $235.23.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.